BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 25636086)

  • 41. Genetic and epigenetic alterations in primary colorectal cancers and related lymph node and liver metastases.
    Miranda E; Bianchi P; Destro A; Morenghi E; Malesci A; Santoro A; Laghi L; Roncalli M
    Cancer; 2013 Jan; 119(2):266-76. PubMed ID: 22786759
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Inferring the progression of multifocal liver cancer from spatial and temporal genomic heterogeneity.
    Shi JY; Xing Q; Duan M; Wang ZC; Yang LX; Zhao YJ; Wang XY; Liu Y; Deng M; Ding ZB; Ke AW; Zhou J; Fan J; Cao Y; Wang J; Xi R; Gao Q
    Oncotarget; 2016 Jan; 7(3):2867-77. PubMed ID: 26672766
    [TBL] [Abstract][Full Text] [Related]  

  • 43. PBRM1 loss is a late event during the development of cholangiocarcinoma.
    Luchini C; Robertson SA; Hong SM; Felsenstein M; Anders RA; Pea A; Nottegar A; Veronese N; He J; Weiss MJ; Capelli P; Scarpa A; Argani P; Kapur P; Wood LD
    Histopathology; 2017 Sep; 71(3):375-382. PubMed ID: 28394406
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Aberrant methylation of multiple genes and its clinical implication in hepatocellular carcinoma].
    Lou C; Yang B; Gao YT; Wang YJ; Nie FH; Yuan Q; Zhang CL; Du Z
    Zhonghua Zhong Liu Za Zhi; 2008 Nov; 30(11):831-6. PubMed ID: 19173828
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets.
    Chong DQ; Zhu AX
    Oncotarget; 2016 Jul; 7(29):46750-46767. PubMed ID: 27102149
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification.
    Calderaro J; Couchy G; Imbeaud S; Amaddeo G; Letouzé E; Blanc JF; Laurent C; Hajji Y; Azoulay D; Bioulac-Sage P; Nault JC; Zucman-Rossi J
    J Hepatol; 2017 Oct; 67(4):727-738. PubMed ID: 28532995
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Commentary on "Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation." Kapur P, Peña-Llopis S, Christie A, Zhrebker L, Pavía-Jiménez A, Rathmell WK, Xie XJ, Brugarolas J. Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX. Lancet Oncol 2013; 14(2):159-67. [Epub 2013 Jan 16]. doi: 10.1016/S1470-2045(12)70584-3.
    Boorjian S
    Urol Oncol; 2014 Aug; 32(6):934-5. PubMed ID: 25087671
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical and molecular analysis of combined hepatocellular-cholangiocarcinomas.
    Cazals-Hatem D; Rebouissou S; Bioulac-Sage P; Bluteau O; Blanché H; Franco D; Monges G; Belghiti J; Sa Cunha A; Laurent-Puig P; Degott C; Zucman-Rossi J
    J Hepatol; 2004 Aug; 41(2):292-8. PubMed ID: 15288479
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma.
    O'Dell MR; Huang JL; Whitney-Miller CL; Deshpande V; Rothberg P; Grose V; Rossi RM; Zhu AX; Land H; Bardeesy N; Hezel AF
    Cancer Res; 2012 Mar; 72(6):1557-67. PubMed ID: 22266220
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Altered regulation of Prox1-gene-expression in liver tumors.
    Dudas J; Mansuroglu T; Moriconi F; Haller F; Wilting J; Lorf T; Füzesi L; Ramadori G
    BMC Cancer; 2008 Apr; 8():92. PubMed ID: 18400094
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Primary liver carcinoma in genetic hemochromatosis reveals a broad histologic spectrum.
    Morcos M; Dubois S; Bralet MP; Belghiti J; Degott C; Terris B
    Am J Clin Pathol; 2001 Nov; 116(5):738-43. PubMed ID: 11710692
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A fibrous stromal component in hepatocellular carcinoma reveals a cholangiocarcinoma-like gene expression trait and epithelial-mesenchymal transition.
    Seok JY; Na DC; Woo HG; Roncalli M; Kwon SM; Yoo JE; Ahn EY; Kim GI; Choi JS; Kim YB; Park YN
    Hepatology; 2012 Jun; 55(6):1776-86. PubMed ID: 22234953
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Combined hepatocellular and cholangiocarcinoma: clinical features and prognostic study in a Thai population.
    Chantajitr S; Wilasrusmee C; Lertsitichai P; Phromsopha N
    J Hepatobiliary Pancreat Surg; 2006; 13(6):537-42. PubMed ID: 17139428
    [TBL] [Abstract][Full Text] [Related]  

  • 54. TERT promoter mutations in primary liver tumors.
    Nault JC; Zucman-Rossi J
    Clin Res Hepatol Gastroenterol; 2016 Feb; 40(1):9-14. PubMed ID: 26336998
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of combined hepatocellular and cholangiocarcinoma with hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
    Lee WS; Lee KW; Heo JS; Kim SJ; Choi SH; Kim YI; Joh JW
    Surg Today; 2006; 36(10):892-7. PubMed ID: 16998683
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
    Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
    J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications.
    Churi CR; Shroff R; Wang Y; Rashid A; Kang HC; Weatherly J; Zuo M; Zinner R; Hong D; Meric-Bernstam F; Janku F; Crane CH; Mishra L; Vauthey JN; Wolff RA; Mills G; Javle M
    PLoS One; 2014; 9(12):e115383. PubMed ID: 25536104
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ubiquitin-specific protease 14 expression associated with intrahepatic cholangiocarcinoma cell differentiation.
    Chuensumran U; Saelee P; Punyarit P; Wongkham S; Pairojkul C; Chauin S; Petmitr S
    Asian Pac J Cancer Prev; 2011; 12(3):775-9. PubMed ID: 21627382
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Molecular features of primary hepatic undifferentiated carcinoma.
    Tsai JH; Jeng YM; Lee CH; Liau JY
    Mod Pathol; 2022 May; 35(5):680-687. PubMed ID: 34949765
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Probing the Tumor Suppressor Function of BAP1 in CRISPR-Engineered Human Liver Organoids.
    Artegiani B; van Voorthuijsen L; Lindeboom RGH; Seinstra D; Heo I; Tapia P; López-Iglesias C; Postrach D; Dayton T; Oka R; Hu H; van Boxtel R; van Es JH; Offerhaus J; Peters PJ; van Rheenen J; Vermeulen M; Clevers H
    Cell Stem Cell; 2019 Jun; 24(6):927-943.e6. PubMed ID: 31130514
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.